Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Registrati

Quotazioni in diretta

NBIX Neurocrine Biosciences Inc

148,73

1,15 (0,78%)

25 Gen 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/15/2025

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/15/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Kyle Gano

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Neurocrine Biosciences (NASDAQ:NBIX)
Storico
Da Dic 2024 a Gen 2025

Clicca qui per i Grafici di Neurocrine Biosciences

Grafico Azioni Neurocrine Biosciences (NASDAQ:NBIX)
Storico
Da Gen 2024 a Gen 2025

Clicca qui per i Grafici di Neurocrine Biosciences

Notizie Neurocrine Biosciences Inc - NBIX

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Giovedì 23 Gennaio 2025 (3 giorni fa) • PR Newswire (US)

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
Martedì 21 Gennaio 2025 (5 giorni fa) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 17 Gennaio 2025 (1 settimana fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 15 Gennaio 2025 (2 settimane fa) • Edgar (US Regulatory)

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Mercoledì 8 Gennaio 2025 (3 settimane fa) • PR Newswire (US)

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lunedì 6 Gennaio 2025 (3 settimane fa) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 3 Gennaio 2025 (3 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 31 Dicembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 8-K - Current report
Venerdì 20 Dicembre 2024 (1 mese fa) • Edgar (US Regulatory)

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Venerdì 20 Dicembre 2024 (1 mese fa) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 19 Dicembre 2024 (1 mese fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 19 Dicembre 2024 (1 mese fa) • Edgar (US Regulatory)

Più Neurocrine Biosciences Inc Articoli Notizie

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea